Paper41373641
From Pathways to Patients in Atopic Dermatitis: Advanced Systemic Therapies.
Prados-Carmona A and 3 others. Int J Mol Sci, 2025. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. From Pathways to Patients in Atopic Dermatitis: Advanced Systemic Therapies. Papers, record 41373641. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41373641
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Dermatitis, Atopic | Major topic |
| Humans | |
| Janus Kinase Inhibitors | |
| Antibodies, Monoclonal | |
| Signal Transduction | |
| Cytokines |
Source PubMed
References182
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 39080181 | Long-Term Efficacy and Safety of Stapokibart in Adults with Moderate-to-Severe Atopic Dermatitis: An Open-Label Extension, Nonrandomized Clinical Trial. | BioDrugs | 2024 | https://conductscience.org/library/papers/39080181 | PubMed |
| 2 | 28670717 | Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis. | Allergy | 2018 | https://conductscience.org/library/papers/28670717 | PubMed |
| 3 | 36630140 | Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere). | JAMA Dermatol | 2023 | https://conductscience.org/library/papers/36630140 | PubMed |
| 4 | 36082590 | Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials. | Br J Dermatol | 2022 | https://conductscience.org/library/papers/36082590 | PubMed |
| 5 | 25659898 | Modulation of pulmonary fibrosis by IL-13Rα2. | Am J Physiol Lung Cell Mol Physiol | 2015 | https://conductscience.org/library/papers/25659898 | PubMed |
| 6 | 39039360 | Dupilumab in Patients with Atopic Dermatitis: A Multicentric, Long-Term, Real-World Portuguese Study. | Dermatol Ther (Heidelb) | 2024 | https://conductscience.org/library/papers/39039360 | PubMed |
| 7 | 40990093 | Biologics to Treat Atopic Dermatitis: Effectiveness, Safety, and Future Directions. | Allergy | 2026 | https://conductscience.org/library/papers/40990093 | PubMed |
| 8 | 27956146 | Structural Characterisation Reveals Mechanism of IL-13-Neutralising Monoclonal Antibody Tralokinumab as Inhibition of Binding to IL-13Rα1 and IL-13Rα2. | J Mol Biol | 2017 | https://conductscience.org/library/papers/27956146 | PubMed |
| 9 | 27490125 | The 'omics' revolution: redefining the understanding and treatment of allergic skin diseases. | Curr Opin Allergy Clin Immunol | 2016 | https://conductscience.org/library/papers/27490125 | PubMed |
| 10 | 35948826 | Switching from reference adalimumab to biosimilar. Assessment of clinical outcomes in psoriasis. | Int J Dermatol | 2023 | https://conductscience.org/library/papers/35948826 | PubMed |
| 11 | 37908364 | Innate lymphoid cells: a new key player in atopic dermatitis. | Front Immunol | 2023 | https://conductscience.org/library/papers/37908364 | PubMed |
| 12 | 40251175 | Real-World pharmacovigilance analysis of drug-related conjunctivitis using the FDA adverse event reporting system database. | Sci Rep | 2025 | https://conductscience.org/library/papers/40251175 | PubMed |
| 13 | 38534078 | Long-term therapeutic response to dupilumab in patients affected by prurigo nodularis: A real-world retrospective study. | J Eur Acad Dermatol Venereol | 2024 | https://conductscience.org/library/papers/38534078 | PubMed |
| 14 | 38216802 | Targeted Systemic Therapies for Adults with Atopic Dermatitis: Selecting from Biologics and JAK Inhibitors. | Am J Clin Dermatol | 2024 | https://conductscience.org/library/papers/38216802 | PubMed |
| 15 | 32651105 | Safety, tolerability and efficacy of repeated intravenous infusions of KHK4083, a fully human anti-OX40 monoclonal antibody, in Japanese patients with moderate to severe atopic dermatitis. | J Dermatol Sci | 2020 | https://conductscience.org/library/papers/32651105 | PubMed |
| 16 | 39405928 | Comparative effectiveness of upadacitinib versus dupilumab for moderate-to-severe atopic dermatitis: A retrospective cohort study. | Int Immunopharmacol | 2024 | https://conductscience.org/library/papers/39405928 | PubMed |
| 17 | 26051792 | IL-33 and Thymic Stromal Lymphopoietin in mast cell functions. | Eur J Pharmacol | 2016 | https://conductscience.org/library/papers/26051792 | PubMed |
| 18 | 37032446 | Early improvements in signs and symptoms predict clinical response to baricitinib in patients with moderate-to-severe atopic dermatitis. | Clin Exp Dermatol | 2023 | https://conductscience.org/library/papers/37032446 | PubMed |
| 19 | 38556434 | IL-4-induced decrease in both the number and CTLA-4 expression of Treg impairs suppression of Th2 type inflammation in severe atopic dermatitis. | J Dermatol Sci | 2024 | https://conductscience.org/library/papers/38556434 | PubMed |
| 20 | 36559247 | OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis-Focus on Rocatinlimab and Amlitelimab. | Pharmaceutics | 2022 | https://conductscience.org/library/papers/36559247 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42909837 | Current Challenges in Atopic Dermatitis: An Italian Delphi Consensus with a Special Focus on Moderate Disease. | Dermatol Ther (Heidelb) | 2026 | https://conductscience.org/library/papers/42909837 | PubMed |
| 42511475 | Atopic Dermatitis Beyond the Skin Barrier: Precision Medicine Approaches to Immunological Profiling and Therapeutic Innovation. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42511475 | PubMed |
| 41972685 | Gut Dysbiosis and the Molecular Landscape of the Gut-Skin Axis: Comparative Insights and Therapeutic Implications for Atopic Dermatitis and Psoriasis. | Cells | 2026 | https://conductscience.org/library/papers/41972685 | PubMed |
| 41897446 | From Dysbiosis to Inflammation: Gut Microbiota and Oxidative Stress in Atopic Dermatitis. | Antioxidants (Basel) | 2026 | https://conductscience.org/library/papers/41897446 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41373641
GET https://conductscience.org/api/papers/v1/41373641/references?page=2